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How to control 
lymphangiogenesis: A novel role 
for rapamycin
D Kerjaschki1
Analysis of the lymphatic microvasculature has become possible only 
recently by the discovery of novel proteins specifically expressed 
in lymphatic endothelial cells only. Therapeutic manipulation of de 
novo lymphangiogenesis might become clinically relevant in the 
future in diverse situations, such as renal transplant rejection. In this 
issue Huber et al. demonstrate that rapamycin acts as an efficient 
inhibitor of lymphangiogenesis. 
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Until recently, research on the biology 
and pathology of lymphatic vessels and 
lymphatic endothelial cells (LECs) led 
a secretive life, and endothelial biol-
ogy was synonymous with studies on 
endothelial cells of blood vessels (BECs). 
However, this has changed in recent 
years, because of the discovery of the 
lymphatic endothelial-specifi c growth 
factors vascular endothelial growth fac-
tor C (VEGF-C) and VEGF-D, and their 
corresponding tyrosine kinase receptor 
VEGFR-3, as well as the identifi cation 
of several proteins that are specifi cally 
expressed by LECs only and may serve 
as ‘markers’ for immunohistochemical 
localization and isolation of LECs.1,2 
On this basis, the fi eld is currently in an 
exponential growth phase, because with 
these new instruments profound biologi-
cal and pathological problems have now 
become tangible.
Th e central importance of VEGF-C in 
lymphangiogenesis was demonstrated 
in classical experiments by Alitalo and 
associates,3 who showed that transgene 
epidermis-specific overexpression in 
mice produces massive dermal lym-
phangiogenesis. Subsequently, several 
groups have reported that overexpression 
of VEGF-C and VEGF-D in experimen-
tal tumors causes lymphangioma-like 
proliferation of lymphatic vessels. Some 
reports indicate that the classic blood 
vessel endothelial growth factor VEGF-A 
— which specifi cally ligates to VEGFR-
1 and VEGFR-2 but not VEGFR-3 
— is also able to induce lymphangio-
genesis. One possible explanation is that 
VEGFR-3 and VEGFR-2 form a hybrid 
heterodimeric complex that accepts both 
VEGF-A and VEGF-C, initiates intracel-
lular signaling, and fi nally causes prolif-
eration of LECs. Recently, several other 
factors, such as platelet-derived growth 
factor and basic fi broblast growth factor, 
were also found to promote lymphang-
iogenesis; however, their exact contribu-
tion in real life remains to be established. 
In conclusion, currently the VEGF-C 
and VEGF-D/VEGFR-3 axis appears to 
be the most prominent and biologically 
relevant growth factor–receptor pair 
for lymphangiogenesis, and survival of 
endothelial cells, and provides thus a 
prime therapeutic target.
A major source for VEGF-C are 
pericytes of blood vessels and this 
may explain why LECs associate with 
BECs in in vitro tube-forming assays 
and lymphatic vessels usually follow 
large blood vessels in tissues.2 Also, 
tumor cells express VEGF-C. However, 
VEGF-C is extensively proteolytically 
processed; only selected forms are able 
to stimulate LECs, and currently it is 
not clear whether tumor cells are able 
to produce this specificity of VEGF-
C. Yet another unexpected source of 
VEGF-C in infl ammatory and neoplas-
tic conditions are tissue macrophages 
presumably derived from a subset of 
CD14+ circulating monocytes express-
ing VEGFR-3.4
Lymphangiogenic extension of the 
mature vasculature apparently follows 
two distinct growth patterns, one of 
which is similar to that of blood capillar-
ies and involves tip cells on the leading 
edge of the growing vessel. Th ese cells 
are specialized endothelial cells that 
emit fi lopodia to scout the environment 
and pave the way for further vascular 
extension. In the blood vasculature, 
stimulation of VEGFR-2 is pivotal for 
this process, whereas in lymphatic ves-
sels, this form of growth is mediated 
by VEGFR-3 and its specifi c ligands. 
Alternatively, the preexisting lymphatic 
vasculature may increase in diameter by 
mitosis of endothelial cells. Currently it 
is not clear whether the same receptors 
as those used in tip-cell formation are 
also necessary for this phenomenon.
In contrast to the blood vasculature, 
tissue macrophages provide a third party 
that contributes, at least under patho-
logical conditions, to the extension of 
lymphatic vessels. Th is was initially sug-
gested by incorporation of lymphatic 
endothelial precursors into rapidly 
extending lymphatics in human renal 
transplants5 and was confi rmed experi-
mentally by elegant experiments on lym-
phangiogenesis in the corneas of mice.6 
Th e molecular mechanisms of transdif-
ferentiation of macrophages to LECs are 
currently unknown. When these fi ndings 
are taken together, lymphangiogenesis 
follows a pattern similar to that of blood 
capillary angiogenesis and also involves 
macrophages as precursors, at least under 
pathological conditions.
What is the relevance of lymphatic 
vessels in the kidney cortex? Recent 
1Department of Pathology, Medical University 
of Vienna–Allgemeines Krankenhaus, Vienna, 
Austria
Correspondence: D Kerjaschki, Medical 
University of Vienna–Allgemeines Krankenhaus, 
Währinger Gürtel 18-20, A-1090 Vienna, Austria. 
E-mail: dontscho.kerjaschki@meduniwien.ac.at
718   Kidney International (2007) 71
commentar y
investigations using LEC-specific 
immunohistochemical markers have 
shown that normal human and rodent 
renal cortex contains few lymphatic 
vessels that are exclusively associated 
with large and middle-sized arteries; 
however, there are no lymphatic vessels 
in the tubulointerstitial space.7 Th is is 
unexpected, as tracers intraparenchy-
mally microinjected into renal cortex 
show up quickly within the lymphatic 
vasculature, but only aft er a lag period 
in blood vessels. Th is suggests massive 
tubulointerstitial solute fl ow, and highly 
effi  cient tracer uptake by the few corti-
cal lymphatics.
The sparse lymphatic vasculariza-
tion of the renal cortex is dramatically 
increased in rat remnant kidneys aft er 
subtotal nephrectomy8 and is associ-
ated with tubulointerstitial macrophage 
infi ltration and fi brosis. Intriguingly, the 
arguably most extensive de novo lym-
phangiogenesis occurs in renal trans-
plants that have undergone episodes of 
rejection.5 Th e driving force for prolif-
eration is the secretion of VEGF-C by 
macrophages in the tubulointerstitial 
space. As a consequence, there are both 
extension of established lymphatic ves-
sels at their tips, and widening of their 
diameter. In this scenario, circulation-
derived lymphatic endothelial precur-
sor cells were discovered, which are 
presumably recruited from tissue mac-
rophages and transdifferentiate into 
LECs.5 Lymph angiogenesis in this situ-
ation helps to clear the infl ammatory 
infi ltrate of the transplant by exporting 
the cells out of the kidney into the next 
lymph nodes. However, as an unex-
pected side eff ect, these newly formed 
lymphatic vessels are intimately associ-
ated with the formation of more or less 
organized lymphocytic infi ltrates that 
appear well defi ned and nodular in some 
histological sections and more diff use in 
others. Th ese infi ltrates contain variable 
numbers of B and T lymphocytes that 
frequently undergo massive prolifera-
tion, as indicated by the expression of 
the nuclear proliferation marker Ki-76.
The function of the cortical peri- 
and para-lymphovascular lymphocytic 
infi ltrates is not clear. Initially it was 
suspected that they perpetuate the 
alloimmune response within the trans-
planted organ5 and could be associated 
with chronic transplant rejection, and 
it was hypothesized that stasis of lymph 
fl uid in newly formed vessels provides 
a large pool of alloantigens for the peri-
lymphovascular lymphatic aggregates.9 
However, a systematic study on proto-
col biopsies recently has revealed that 
increased lymphovascular density in 
renal cortex of transplants actually pre-
dicts a favorable outcome of the kidney 
function.10 Th is may be primarily due to 
clearing of aggressive infl ammatory cells 
by the lymphatic vasculature. However, 
recent investigations have indicated that 
Fox-P3+/E-selectin+ T lymphocytes 
of potential regulatory function are 
encountered rather frequently in these 
infiltrates (our unpublished data) 
that thus may be involved in immuno-
logical tolerance.
Th e decision of whether lymphangio-
genesis in renal transplants is good or 
bad for the patient clearly is important, 
because this will direct any future ther-
apeutic anti- or prolymphangiogenic 
approach. So far, several antilym-
phangiogenic therapies are established 
in experimental systems.11 Expression 
of a soluble VEGF-C ‘trap’ consisting of 
the ectodomain of VEGFR-3 fused onto 
an Fc fragment of IgG, and encapsulated 
into an adenovirus, very effi  ciently abol-
ishes lymphangiogenesis, for instance 
in tumor xenografts. Also, a human-
ized monoclonal antibody is available 
that blocks the binding of VEGF-C to 
VEGFR-3. These compounds inhibit 
de novo lymphangiogenesis but do not 
affect established lymphatic vessels. 
Th ese therapeutic approaches could be 
useful for the treatment of diseases in 
which lymphangiogenesis is detrimental, 
and systematic clinical trials will have to 
show their effi  cacy. For the time being, 
however, use of clinically approved 
drugs with antilymph angiogenic activ-
ity would be advantageous. Th erefore, 
it is of considerable broad interest that 
Huber et al.12 (this issue) now report 
their discovery that rapamycin is 
a highly efficient antilymphangio-
genic compound.
Central to the antiangiogenic action 
of rapamycin is the mammalian tar-
get of rapamycin (mTOR),13 a protein 
kinase belonging to the phosphati-
dylinositol-3′-kinase (PI3K) family. In 
endothelial cells, one pathway of regula-
tion of cell growth and proliferation is 
mediated by the regulatory associated 
protein of mTOR (raptor)–G protein 
β-subunit-like protein (GβL)–mTOR 
complex, which is a target of rapamy-
cin. Important downstream eff ectors of 
the mTOR system are the translation 
regulators p70S6 kinase and eukaryo-
tic initiation factor 4E-binding protein. 
The mTOR pathway is regulated by 
the PI3K/AKT kinase system, which, 
for example, is upregulated in tumors. 
Activation of PI3K/AKT causes activa-
tion of mTOR and promotes cell growth 
and proliferation. Huber et al.12 dem-
onstrate that rapamycin interferes with 
the intracellular VEGF-C-activated 
pathway of LECs, and that this find-
ing is analogous to previous results on 
VEGF-A and BECs. Collectively, this is 
the fi rst indication that proliferation of 
LECs is controlled by intracellular sig-
naling networks similar, if not identical, 
to those of BECs. Th is also means that 
rapamycin treatment will have a dual 
effect on blood and lymphatic vessel 
proliferation, which in some instances, 
such as inhibition of tumor growth, may 
be desirable.
In conclusion, the novel data pre-
sented by Huber et al.12 introduce 
rapamycin as an antiangiogenic tool, 
both for experiments and for the clini-
cal setting. Huber et al.12 also explain 
some of the unfavorable side eff ects of 
rapamycin treatment aft er surgery. It 
remains to be seen whether or not anti-
lymphangiogenic rapamycin treatment 
will turn out to be useful in the clinic.
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Metabolic risk factors and renal 
disease
JR Sowers1
Accumulating evidence supports that components of the metabolic 
syndrome coexist with both albuminuria and chronic kidney 
disease (CKD). The article by Tomaszewski et al. indicates that 
this interrelation exists in young obese men before overt renal or 
cardiovascular disease and also suggests that early treatment of 
hypertension is especially compelling to prevent the evolution of 
renal hyperfiltration to CKD.
Kidney International (2007) 71, 719–720. doi:10.1038/sj.ki.5002006
In addition to the generally recognized 
relationship between the metabolic 
syndrome and the future development 
of type 2 diabetes and cardiovascular 
disease, there is emerging evidence of 
an important relationship among the 
metabolic syndrome, obesity, and both 
albuminuria and chronic kidney disease 
(CKD).1–10 Early data suggesting this 
relationship1,2 have been confi rmed in 
large population-based studies.3–8 For 
example, the relationship between body 
mass index and end-stage renal disease 
(ESRD) was observed in a Japanese pop-
ulation of over 100,000 people followed 
for 17 years. Th e cumulative incidence 
of ESRD increased signifi cantly with ris-
ing body mass index; aft er adjustment 
for age, systolic blood pressure, and 
proteinuria, the odds ratio of body mass 
index for developing ESRD was 1.273 in 
men.3 Likewise, in 10,096 nondiabetic 
participants in the Atherosclerosis Risk 
In Communities Study, the odds ratio 
for developing CKD in those with the 
metabolic syndrome compared with 
those without the syndrome was 1.43.6 
Similarly, in a cohort of 320,252 adults 
from the United States followed up over 
a 15- to 35-year period, the rate of ESRD 
increased in a manner proportional to 
rising body mass index.7 These data 
confi rm the original observation that 
metabolic syndrome risk factors (ele-
vated triglycerides and low levels of 
high-density lipoprotein cholesterol) 
accelerate progression to ESRD.1
Increasing components of the meta-
bolic syndrome augment the risk for 
microalbuminuria4 and proteinuria.5 
For example, the association between 
components of the metabolic syndrome 
and the risk for microalbuminuria, as 
well as CKD, was assessed in persons 
participating in the Third National 
Health and Nutrition Examination 
Survey (NHANES III).4 In multivari-
ate-adjusted analysis, the odds ratio for 
microalbuminuria and CKD was 1:89 
and 2:60, respectively. Further, the risk 
for microalbuminuria and CKD was 
proportional to the number of individ-
ual components of the metabolic syn-
drome. Similar observations were made 
in a Japanese population in which the 
infl uence of the metabolic syndrome 
was documented in men younger than 
60 years.8
Tomaszewski and colleagues11 (this 
issue) have now advanced our under-
standing of these relationships between 
metabolic and renal disease risk factors. 
Th ey carefully phenotyped 1,572 young 
(mean age 18.4 years), relatively healthy 
men for metabolic risk factors and renal 
function as analyzed by calculated cre-
atinine clearance based on the Cock-
croft –Gault equation. Th ey observed 
that enhanced metabolic risk — clus-
tering of at least three metabolic risk 
factors — was present in 8.7% of these 
young men and was associated with an 
odds ratio of 6.9 for glomerular hyperfi l-
tration. Th is early renal abnormality was 
associated with adiposity (leptin levels 
and anthropometric determinants) and 
elevated blood pressure, each compo-
nents of the metabolic syndrome.
In their discussion of the observed 
associations,11 the authors propose 
that a major driver of hyperfi ltration 
is probably adipose tissue — a source 
of infl ammatory adipokines and leptin, 
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